Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 85,265 shares of the firm's stock in a transaction that occurred on Thursday, November 19th. The shares were bought at an average price of $1.09 per share, for a total transaction of $92,938.85. Following the acquisition, the director directly owned 37,111,299 shares in the company, valued at $40,451,315.91. This trade represents a 0.23% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Gregg Williams also recently made the following trade(s):
- On Wednesday, November 18th, Gregg Williams bought 33,169 shares of Vivani Medical stock. The shares were bought at an average cost of $1.05 per share, for a total transaction of $34,827.45.
- On Tuesday, November 17th, Gregg Williams purchased 29,929 shares of Vivani Medical stock. The stock was bought at an average price of $1.05 per share, for a total transaction of $31,425.45.
- On Monday, November 16th, Gregg Williams purchased 2,100 shares of Vivani Medical stock. The stock was acquired at an average price of $1.01 per share, with a total value of $2,121.00.
- On Friday, November 13th, Gregg Williams bought 48,100 shares of Vivani Medical stock. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $47,619.00.
Vivani Medical Price Performance
NASDAQ VANI opened at $1.09 on Friday. Vivani Medical, Inc. has a 1 year low of $0.80 and a 1 year high of $1.66. The company has a fifty day moving average of $1.16 and a 200 day moving average of $1.23. The company has a market capitalization of $98.32 million, a PE ratio of -3.41 and a beta of 2.51.
Vivani Medical (NASDAQ:VANI - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01.
Analyst Ratings Changes
Several analysts have weighed in on VANI shares. Wall Street Zen lowered Vivani Medical from a "hold" rating to a "sell" rating in a report on Sunday, November 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $3.75.
View Our Latest Analysis on VANI
About Vivani Medical
(
Get Free Report)
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vivani Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.
While Vivani Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.